Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

 

Columbia University
Irving Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818


bottom bar
top
make an appointment

Clinical Trials

Clinical Trials Currently Recruiting



Mild Cognitive Impairment: VALMCI valacyclovir (Alzheimer’s Association)
Anti-viral therapy in Mild Cognitive Impairment
Phase 2. Oral Medication. Twice daily. Duration: 52 Weeks (12 months). NCT04710030.
Amnestic Mild Cognitive Impairment (early MCI and late MCI); positive screening tests results for antibodies to HSV1 or HSV2 and AD biomarkers. MMSE: 23-30. Age: 50-95
(Dr. Devanand) Call Julianna Pollina at 646-774-8638

Alzheimer’s disease: VALAD valacyclovir (NIH/NIA)
Anti-viral therapy in Alzheimer’s disease.
Phase 2. Oral Medication. Twice daily. Duration: 78 Weeks (18 months). NCT03282916.
Mild Alzheimer’s disease (AD); positive screening tests results for antibodies to HSV1 or HSV2. MMSE: 18-28. Age 18-105.
(Dr. Devanand) Call Julianna Pollina 646-774-8638

Alzheimer's Disease: S-CitAD escitalopram (NIA)
Escitalopram for Agitation in Alzheimer’s Disease.
Phase 3. Combination intervention; Psychosocial Intervention and Oral Medication. Duration: 24 Weeks (6 months). NCT03108846.
Alzheimer's disease (AD) with agitation. MMSE: 5-28. Age 55-95.
(Dr. Devanand) Call Izael Nino at 646-774-8671

Mild Cognitive Impairment/Early Onset Alzheimer’s Disease: Focused UltraSound (NIA)
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
Duration:5 visits. NCT04118764
Amnestic Mild Cognitive Impairment/Alzheimer’s Disease. MMSE: 12-26. Age: ≥50.
Procedures include: MRI, head ultrasound.
(Dr. Honig/Dr. Konofagou) Call Maria Karakatsani or Pablo Abreu 212-342-1612

UPCOMING STUDY: Alzheimer’s Disease: AL002-2 (Alector Inc)
A Phase 2 Study for Safety and Tolerability of AL002.
Phase 2. IV Infusion. Every 4 weeks. Duration: about 52-96 weeks. NCT04592874.
AD. MMSE: 16-28. Age: 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

UPCOMING STUDY: Alzheimer’s Disease: Autonomy JNJ-63733657 (Janssen Research & Development, LLC)
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease.
Phase 2. IV Infusion. Every 4 weeks. Duration: about 4.5 years. NCT04619420.
AD. CDR: 0.5. Age: 55-80.
(Dr. Honig) Call Katrina Cause 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

UPCOMING STUDY: Alzheimer’s Disease: AVP-786 (Avanir Pharmaceuticals)
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type.
Phase 3. Oral medication. Twice daily. Duration: about 20 weeks. NCT04408755.
AD with agitation. MMSE: 8-24. Age: 50-90.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Solciris Dominguez 212-342-2380, Evelyn Dominguez 212-305-2371

UPCOMING STUDY: Mild Cognitive Impairment/ Alzheimer’s Disease: SIGNAL-AD Pepinemab (Vaccinex, Inc)
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease.
Phase 1b/2a. IV Infusion. Monthly. Duration: about 40 weeks.NCT04381468.
MCI due to AD/AD. MMSE: ≥22. Age: 55-85.
Procedures include: MRI (total: 2), LP (with positive historical Amyloid PET before screening: 1; otherwise, 2).
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Frontotemporal Dementia: FOXY
A Phase 2 Clinical Trial of Oxytocin for Frontotemporal Dementia.
Phase 2/3. Intranasal spray. Twice daily. Duration: 24 Weeks. NCT03260920.
Frontotemporal Dementia (FTD). MMSE: >10. Age: 30-80
(Dr. Huey) Call Hannah Silverman (212) 305-6284

Frontotemporal Dementia: lithium (ADDF)
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Phase 2/3. Oral Medication. Once daily. Duration: 12 Weeks. NCT02862210.
FTD. MMSE: 5-26. Age: 40-85
(Dr. Huey) Call Hannah Silverman (212) 305-6284

Frontotemporal Dementia: INFRONT-3 AL001-3 (Alector Inc)
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia.
Phase 3. IV Infusion every 4 weeks. Duration: about 48 or 96 weeks
NCT04374136.
FTD. Carrier of a progranulin gene mutation. CDR 0, 0.5, 1, or 2. Age: 18-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

UPCOMING STUDY: Dementia with Lewy Bodies or Parkinson’s Disease Dementia: PINO E2027 (Eisai Inc)
An Open-Label Study to Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects with Dementia with Lewy Bodies or Parkinson’s Disease Dementia with or without Amyloid Copathology.
Phase 3. Oral Medication. Once daily. Duration: about 24 weeks.
DLB/PDD. MMSE: 14-26. Age: 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Observational Studies Currently Recruiting



Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition: LEADS (NIH/NIA)
Longitudinal Early Onset Alzheimer’s Disease
Duration: 2 years, yearly visit. NCT03507257
Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition. CDR 0, 0.5 or 1.0 (MCI/AD). Age: 40-64.
Procedures include: MRI, Amyloid and Tau Pet scan, optional LP.
(Dr. Honig) Call Arlene Mejia 212-305-9168.

Mild Cognitive Impairment/Alzheimer’s Disease/ Normal Cognition: ADRC clinical core (NIH/NIA)
Alzheimer’s Disease Research Center Clinical Core
Duration: 2 hours visit (in person). Visits are every year for the duration of the study.
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. Age: 55-90.
Procedures include: MRI, LP.
(Dr. Noble) Call Arlene Mejia 212-305-9168.

Mild Cognitive Impairment/ Mild Alzheimer’s Disease/ Normal Cognition: ADNI3 (NIH/NIA)
Alzheimer’s Disease Neuroimaging Initiative 3
Duration: 2. NCT02854033
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. MMSE: ≥24 (CN and MCI) 20-24 (AD). Age: 55-90.
(Dr. Stern) Call Anton Kociolek 212-342-0522

Mild Alzheimer's Disease/Normal Cognition: AD Autoimmune (NIH/NINDS)
Autoimmune features in neurodegenerative disorders
Duration: In-person: 1 to 2 visits. 1.5hrs per visit. NCT04239079
If living in the five boroughs of NYC, Long island area, Westchester, Rockland or Putnam county in NYS, home visit is available: 1 video visit (45min) + 2 mobile phlebotomy home visit (15min each).
Mild Alzheimer's Disease/Amnestic Mild Cognitive Impairment/Normal Cognition. AD: MMSE: 20-26, CDR 0.5-1. Age: ≥55
Procedures include: 100ml blood draw.
(Dr. Marder) Call Heather Xu 646-774-5023

Amnestic, visual, and language variants of Mild Cognitive Impairment/AD: ADVISe (NIH/NIA)
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease
Duration: 2 years, baseline visits and 2 year follow up. NCT04576793
Amnestic Mild Cognitive Impairment/Amnestic Alzheimer's Disease/Posterior Cortical Atrophy/Logopenic Variant Primary Progressive Aphasia/Normal Cognition. CDR 0, 0.5 or 1.0. Age: 50-70.
Procedures include: MRI, Amyloid, Tau, and Inflammation PET scans, LP.
(Dr. Kreisl) Call Elena Golub 212-305-9194

Upcoming Study: Mild Cognitive Impairment/Alzheimer's Disease: PAM (NIH/NIA)
Discovery and validation of genetic variants affecting microglial activation in Alzheimer's disease
Duration: 5 years, baseline MRI/PET scan and 4 year follow up for blood draw/cognitive testing.
Amnestic Mild Cognitive Impairment/Alzheimer's Disease/Normal Cognition (with prior LP or amyloid PET scan). CDR 0, 0.5 or 1.0. Age: ≥ 50.
Procedures include: MRI, Inflammation PET scan
(Dr. De Jager/Kreisl) Call Galen Ziaggi 212-305-9194

Alzheimer’s Disease: DIAN (NIH/NIA)
Dominantly Inherited Alzheimer Network
Duration: Years. Every 1 to 3 years visits. NCT00869817
Family members of a person with AD (proband) due to PSEN1, PSEN2, or APP mutations. MMSE: any. Age: ≥18; younger but no more than 10 years younger than proband’s AAO.
(Dr. Noble) Call Arlene Mejia 212-305-9168

Alzheimer’s Disease: EFIGA (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics
Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study.
Hispanic families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: LOAD (NIH/NIA)
Late Onset Alzheimer’s Disease
Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study.
Any ethnic background families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate; Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Pedro Mena 212-305-2309, Izri Martinez (For African American participants) 212-305-2349

Alzheimer’s Disease: READR (NIH/NIA)
Resource for Early Onset Alzheimer’s Disease Research: Early Onset Alzheimer’s Disease Whole Genome Sequencing
The goal is to identify unknown mutations (other than APP, PSEN1 and PSEN2) Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study.
Age: Onset of memory problems before the age of 65.
(Dr. Reitz) Call Penelope Baez 201-640-4335

Alzheimer's Disease: Apathy in Alzheimer's Disease (DOD/NIA)
Investigating a New Biological Pathway for Treatment Targeting to Positively Impact Quality of Life
Duration: 1 visit. 2 hours.
Alzheimer's Disease. MMSE: 9-26. Age: any.
(Dr. Clelland) Call Bimala Rawal 212-304-7722

Subjective Cognitive Complaint: SCD Project (NIH/NIA)
Characterizing Subjective Cognitive Decline in Older Adults
Duration: 1 visit. 1.5hrs.
Subjective Cognitive Complaint. Age: ≥56.
(Dr. Cosentino) Call Jillian Joyce 212-342-1969

Dementia with Lewy Bodies: Targeting Lewy Body Pathology (NIH/NINDS)
Targeting Lewy Body Specific Pathology Using Biomarkers
Duration: 5 years.
Mild Cognitive Impairment due to Dementia with Lewy Bodies/Dementia with Lewy Bodies/Parkinson’s Disease Dementia.
Procedures include: optional LP.
(Dr. Marder/Dr. Honig) Call Helen Mejia-Santana 212-305-9183

Neurodegenerative diseases/Mild Cognitive Impairment/Normal Cognition: NAPS (NIH)
Neurodegeneration-Associated Psychiatric Symptoms
Duration: 1 visit, 4-5 hours.
Alzheimer's disease, Frontotemporal dementia, Primary Progressive Aphasia, Dementia with Lewy Bodies, Parkinson’s disease, Huntington's disease, Mild Cognitive Impairment, Healthy Controls. Age: 40-85. (Dr. Huey) Call Yedili Genao-Perez 212-305-3187

Tauopathies/Progressive Supranuclear Palsy / Corticobasal Syndrome: 4RTNI2 (NIH/NIA)
4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2
Duration: 1-3 day visits every 6 months, for 1-2 years. NCT02966145
Progressive Supranuclear Palsy/ variant PSP syndrome/r Non-fluent Variant Primary Progressive Aphasia/ Corticobasal Syndrome. Age: 40-80, CDR 0, 0.5, or 1.
Procedures include: MRI, tau and amyloid PET scan, optional LP.
(Dr. Huey) Call Masood Manoochehri 212-305-5710

Frontotemporal Dementia: ALLFTD ((NIH/NIA/NINDS))
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Protocol
Duration: 3-6 hour visits, for 1-5 years. NCT04363684
National consortium enrolling: Behavioral Variant Frontotemporal Dementia/Non-Fluent Variant Primary Progressive Aphasia/Semantic Variant Primary Progressive Aphasia/ Frontotemporal Dementia-Amyotrophic Lateral Sclerosis.
Also enrolling asymptomatic members of families with mutation in MAPT, GRN, C9orf72, or strong family history of FTLD.
Age: ≥18, CDR 0, 0.5, 1, or 2
Procedures include: MRI, optional LP, optional genetic testing.
(Dr. Huey) Call Masood Manoochehri 212-305-5710

Programs Currently Recruiting


Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia in whom agitation is severe and dominating care. Spanish-speakers are welcome. Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

A Friend for Rachel
A companionship program
MCI, early AD, early PPA, FTD (if not too behavioral), early DLB (if no hallucinations).
Must be mobile and able to go out of home without an aide.
Participants will spend a few hours a week with their student friend either exploring NYC or staying near home.
Call Jill Goldman 212-305-7382

bottom bar